Clinical

Videos

“This type of collaboration [between SEER and GPS assay] is a really nice illustration of the types of projects that we should be undertaking in the future,” says Scarlett Gomez, MD, PhD.

Importance of understanding patterns in prostate genomic testing

 is professor of surgery in the division of urology at Albany Medical College in New York.

Articles

"This large cohort study confirms the safety of AS, as shown in the low rate of metastasis or death, including those who subsequently converted to treatment," writes Badar M. Mian, MD.

Active surveillance for prostate cancer is generally safe, study results show

"Perhaps there is another Nobel Prize waiting to be had if we could reduce the cardiovascular effect of ADT and unlock the answer to the controversy surrounding the comparative safety and impact on cardiovascular health between GnRH agonists and antagonists," writes Michael S. Cookson, MD, MMHC.

Prostate cancer and CV risk: The heart of the matter

In this interview, Ardeshir (Art) Rastinehad, DO, discusses the current state of focal therapy in prostate cancer, the role of fusion biopsy in pushing the treatment forward, and what institutions looking to implement focal therapy should know. 

Interest grows for focal therapy in treating prostate cancer

"What will probably be surprising to the reader is that patients managed in markets with higher average prices for prostatectomy were not more likely to undergo treatment," says Lillian Y. Lai, MD.

Study finds commercial prices for prostatectomies are not associated with treatment patterns

“We're increasingly seeing the addition of molecular and genetic tests to guide us in terms of the cancer treatment that we provide our patients,” says Scarlett Gomez, MD, PhD.

Dr. Scarlett Gomez discusses prostate genomic testing in a world of precision medicine

Following a high intensity interval training exercise regimen was associated with decreased PSA levels in men undergoing active surveillance for prostate cancer.

High-intensity exercise regimen may boost active surveillance outcomes in prostate cancer

The results also showed a trend toward improved overall survival with the combination of the PARP inhibitor and novel hormonal agent; however, the data remain immature.

Olaparib plus abiraterone significantly delays progression in frontline mCRPC

Paige Prostate AI-based software provides pathologists with a supplementary assessment of prostate biopsy images that identifies the area with the highest likelihood of harboring cancer.

FDA authorizes AI-based software for prostate cancer detection

Podcasts

“We need to do a better job sampling the prostate,” says Matthew J. Allaway, MD.

Prostate Cancer